Pliego CA, Yánez VJA, López VT

Language: Spanish
References: 26
Page: 217-226
PDF size: 81.16 Kb.

ABSTRACT

Background: infections caused by multidrug-resistant bacteria strains (MRBS) is a serious problem for patients suffering from oncology diseases. Objectives: the most frequent MRBS isolated at the Laboratorio Clínico of the Hospital de Oncología, Centro Médico Nacional Siglo XXI in Mexico City were analyzed with the aim to identify species and antimicrobial drug sensitivity.
Material and methods: during 27 months, we took 6115 culture samples seeded manually. Strains were identified and their drug resistance tested by an automated method. Next, quality controls recommended by the NCCLS were used: Enterococcus faecalis ATCC 29912-Resistant; Enterococcus faecalis ATCC 51299-Susceptible; Staphylococcus aureus ATCC 29213-Susceptible, and Pseudomonas aeruginosa ATCC 27853-Susceptible. His interpretative standards for drug as susceptible, intermediate, and resistant were applied.
Results: there were 204 resistant bacteria strains from 2997 isolated cultures (7 %). Pseudomonas species were isolated from 72 cultures, 32 strains resistant to all tested drugs. Carbapenems and aminoglycosides were the most effective against the remainder. Enterococci (69) and Staphylococci (63) species were vancomycin-resistant in 2.9 and 21 %, respectively. Enterococci strains were resistant in 7.2% to teicoplanin, while E. faecalis strains were sensitive to high ampicillin dosage in 97 %.
Conclusions: infections caused by Pseudomonas species were most frequently highly resistant bacteria strains. We founded low Enterococci but high Staphylococci vancomycin resistance. E. faecalis multidrug-resistant bacteria strains were ampicillin-susceptible.

REFERENCES

1. Fridkin SK, Steward CD, Edwards JR, et al. Sur-veillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project intensive care antimicrobial epide-miology (ICARE) hospitals. Clin Infect Dis 1999; 29:245-252.

2. 2. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hos-pitals. Clin Infect Dis 1997;25:584-599.

3. 3. Garbut MJ, Ventrapragada M, Littenberg B, Mundy ML. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacte-remia. Clin Infect Dis 2000;30:466-472.

4. 4. Moss WJ, Beers MC, Johnson E, et al. Pilot study of antibiotic cycling in a pediatric intensive care unit. Crit Care Med 2002;30:1877-1882.

5. 5. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.

6. 6. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. New Engl J Med 1999;340:517-523.

7. 7. Boyce JM. Consequences of inaction: importance of infection control practices. Clin Infect Dis 2001;33 (Suppl 3):S133-S137.

8. 8. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;i:57-58.

9. 9. Centers for Disease Control and Prevention. Noso-comial enterococci resistant to vancomycin-United States, 1989-1993. Morb Mortal Weekly Rep 1993; 42:597-599.

10. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clinic Microbiol Rev 2000;13 (4):686-707.

11. Bauer AW, Kirby WM, Sherris JC, Turck M. Anti-biotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493-496.

12. National Committee for Clinical Laboratory Stan-dards 1999. Document M100-S9. Performance standards for antimicrobial susceptibility testing. 9th informational supplement. NCCLS. Wayne Pa.

13. Staneck LS, Weckbach RC, Tilton RJ, Zabransky L, Bayola-Mueller CM, O’Hara JM. Collaborative evaluation of the radiometer Sensititre AP80 for identification gramnegative bacilli. J Clin Microbiol 1993;30:1179-1184.

14. Miller LA, Rittenhouse SF, Utrup LJ, Poupard JA. Comparison of three methods for determination of a single MIC of an antimicrobial agent. J Clin Microbiol 1994;32:1373-1375.

15. Gruson D, Hilbert G, Vargas F, Valentin OR, Bui N, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003;31:1908-1914.

16. Raad I, Hachem R, Hanna H, Girgawy E, Rolston K et al. Treatment of vancomycin-resistant entero-coccal infections in the immunocompromised host: quinupristin-dalfopristin in combination with mino-cycline. Antimicrob Agents Chemother 2001;45: 3202-3204.

17. Montecalvo MA, de Lencastre H, Carraher M, Gedris C, Chung M. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995;16:680-685.

18. Patterson JE, Sweeney AH, Simms M, Carley N, Mangi R, et al. Analysis of 110 series enterococcal infections. Medicine 1995;74:191-200.

19. Ruoff KL, De la Maza L, Murtagh MJ, Spargo JD, Ferraro MJ. Species identities of enterococci isolated from clinical specimens. J Clin Microbiol 1990;28:434-437.

20. Report of WHO Workshop Held in collaboration with the Italian Associazione Culturale. Micro-biología Médica. The current status of antimicrobial resistance surveillance in Europe. Verona, Italy. 12 December 1997. WHO/EMC/BAC/98.1.

21. Stelling JM, O’Brien T. Surveillance of antimi-crobial resistance: The WHONET Program. Clin Infect Dis 1997;24(S):157-63.

22. McGowan JE Jr. Increasing threat of grampositive bacterial infections in the intensive care unit setting. Crit Care Med 2001;29(Suppl):N69-N74.

23. Murthy R. Implementation of strategies to control antimicrobial resistance. Chest 2001;119:405S-411S.

24. Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med 2003;31:S25-S28.

25. Moss WJ, Beers MC, Johnson E, Nichols DG, Perl TM, et al. Pilot study of antibiotic cycling in a pediatric intensive care unit. Crit Care Med 2002;30:1877-1882.

26. Paterson JE. Antibiotic utilization. Is there an effect on antimicrobial resistance? Chest 2001;119:426S-430S.